Introduction
Osteopetrosis (OP) is a genetic disorder of bone turnover characterized by bone fragility and extramedullary hemopoeisis. Secondary neurologic manifestations may be the result of sclerosis of the skull bones. A rare neurodegenerative form (autosomal recessive osteopetrosis) causes primary neurologic manifestations at an early age.
There is preliminary evidence that this form is due to a mutation in the CLCN7 gene [which accounts for only 15% of autosomal recessive (AR) cases]. Herein we report a new mutation in this gene and provide further evidence for this phenotype-genotype correlation. Furthermore, we believe that AR CLCN7-related OP may be more common in individuals of Arab ancestry. (OP, AR 1; Center for Arab Genomic Studies; Al-Rasheed et al., 1998) .
Case report
We report on a 6-year-old Yemeni boy, diagnosed to have OP at 5 months of age ( Fig. 1a and b) . He was first seen in our Institute at the age of 2 years. He is a product of a full-term uneventful pregnancy with spontaneous vaginal delivery, and with a birth weight of 3.0 kg to a healthy consanguineous couple. The review of the medical history reveals that he first presented at the age of 5 months with developmental delay, poor vision, and progressive abdominal distension due to hepatosplenomegaly. The diagnosis was based on the clinical and radiological findings. The medical history also revealed delayed dentition. He had a left femur fracture at 6 months of age after trivial trauma and was put in a cast for 3 weeks. He had adenoidectomy for upper airway obstruction at the age of 4.5 years. At the age of 2 years, he developed bruising and bleeding gums, with severe anemia (hemoglobin of 2.7 gm/dl) and thrombocytopenia (platelet count of 7000 K/ul). Since then, blood and platelet transfusions have been regularly needed. The child has global developmental delay. He sat at the age of 1.5 years, developed a pincer grasp at the age of 2 years, and currently walks with assistance. He has a small vocabulary consisting of a few words. His vision is poor with secondary searching nystagmus. As bone marrow transfusion was not feasible for this patient, symptomatic treatment took place, including trials of erythropoietin and steroids which were not beneficial and were therefore discontinued accordingly. He currently receives blood and platelet transfusions fortnightly and supportive therapy including vitamin D supplementation.
Family history
The parents are young healthy first cousins. They have two healthy living children: a 10-year-old son and a 13-year-old daughter. They reported a similar illness in a deceased daughter, who was not known to us. Her parents provided a medical report with the diagnosis of OP at the age of 3 months. After an uneventful pregnancy and delivery she was born small for age. She had poor growth and development. The diagnosis was based on a combination of clinical features (brain atrophy, optic atrophy, deafness, and hepatosplenomegaly), pancytopenia, and typical radiological findings. She died of bleeding at the age of 7 years. The remainder of the family history is unremarkable. (Fig. 2) 
Patient examination
At the age of 6 years, the propositus was severely pale, but not jaundiced, had widespread bruising, bilateral proptosis, and horizontal searching nystagmus. His weight (12.2 kg) and height (95 cm) were much below the fifth percentile and corresponded to the age of 3 months. (Fig. 3) The head circumference was 49 cm (75th percentile). There were dysmorphic features secondary to the bony changes. These included bossing of the forehead, shallow orbits, and malar hyperplasia. The mouth was persistently open with overcrowded teeth and hypomineralization of the enamel. He had a functional ejection systolic murmur but bilateral clear lung fields. Abdominal examination revealed a liver span of 17 cm and huge splenomegaly reaching the pelvis (11 cm below the left costal margin). No ascites was found. Central nervous system examination revealed wasted upper and lower limbs with generalized hypotonia but preserved deep tendon reflexes. Examination of the cranial nerves revealed nystamus due to optic atrophy. There was no choanal stenosis, seizures, facial palsy, lymphedema, nor ectodermal dysplasia.
In the skeletal survey, all images demonstrated features of OP with severe increase in bone density and striations of the bones, as well as abnormal tabulation and lack of modeling (Fig. 4) . The increased density was especially noted at the base and frontal region of the skull, throughout the pelvic bones and in the vertebrae ( Fig. 4a-d ). Ultrasound examination of the abdomen revealed hepatomegaly and high resistance index of both renal arteries suggesting bilateral renal artery stenosis. Echocardiogram revealed mildly dilated left heart with good cardiac function.
The latest blood results include a complete blood count which showed a severe normochromic normocytic anemia (Hb: 4.8 gm/dl) with mild reticulocytosis (2.18%), and thrombocytopenia 22 K/Ul with normal white blood cell count (19.5 K/Ul). IgG and IgA levels were elevated (26.4 g/l and 4.55 g/l, respectively). The IgM was within the normal range (0.56 g/l). Serum calcium, phosphate, alkaline phosphatase, vitamin D level, urea, and electrolytes were all within normal limits. The serum ferritin level was elevated (655.8 ng/ml) secondary to repeated blood transfusions. The aspirate transaminase was elevated to 92 U/l (normal range: 15-37 U/l), but the remainder of the liver enzymes and the prothrombin times were normal. Bone marrow aspiration resulted in a dry tap.
Genetic testing
All coding exons (2-20) of the TCIRG1 gene were amplified by PCR. The amplified products were then sequenced using the ABI 3730 sequencer (Allentown, USA) and analyzed for sequence variations. DNA sequencing of the TCIGR1 gene revealed no detectable disease causing mutation. The 25 exons of the CLCN7 gene were also amplified by PCR. The amplified products were then sequenced using the ABI 3730 sequencer and analyzed for sequence variations. DNA analysis revealed a homozygous c.688A > G transition in exon 8 of the CLCN7 gene. This change converts a codon for lysine (AAA) to a codon for glutamic acid (GAA). This change has not been previously reported. The gene OSTM1 was not tested as the mutation was already found in CLCN7 gene. Clinical features are mainly related to bone resorption and its secondary complications and therefore include short stature, recurrent fractures, hypocalcemic tetany, and secondary hyperparathyroidism. Macrocephaly and skull deformity may also occur. Sclerotic changes may lead to choanal stenosis, hydrocephalus, optic nerve compression, facial palsy, and hearing loss. Dental problems include hypodontia, delayed tooth eruption, enamel hypoplasia, and dental malformations. Absent bone marrow cavity can lead to extramedullary hematopoesis, hepatosplenomegaly, pancytopenia, and recurrent infections. Diagnosis is made by a combination of clinical features and radiological findings. These include a generalized increase in bone density, a bone within bone appearance mainly in the iliac wings, Erlenmeyer-shaped femoral metaphysis, and transverse bands of osteosclerosis in long bones (De Vernejoul and Schulz, 2007) .
There is currently no effective treatment, and management remains largely supportive. However, hematopoietic stem cell transplantations (HSCTs) can prevent or reverse most of the manifestations of OP and is therefore considered curative (De Vernejoul and Schulz, 2007) .
HSCT using HLA-identical donors results in 73% 5-year disease-free survival. The exception to this is the neuropathic form in which HSCT is not effective (Driessen et al., 2003) .
Interferon-g 1b treatment has been attempted in AR OP (ARO) variants that are unlikely to respond to HSCT. It can slow the progression of the disease while awaiting transplantation. Other modalities of treatment include stimulation of host osteoclasts with calcium restriction, calcitrol, steroids, and parathyroid hormone (Driessen et al., 2003) The adult onset types have a normal life expectancy, but the severe infantile form has a poor prognosis, with most untreated children dying in their first decade of life due to bone marrow suppression (Besbas et al., 2009) .
Genetically, OP is classified into three main forms (AR, autosomal dominant (AD), and intermediate AR) and ranges widely in severity (Besbas et al., 2009 ). In addition, Growth chart of the patient for (a) weight and (b) height.
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a rare X-linked form associated with lymphedema, anhydrotic ectodermal dysplasia, and immunodeficiency (Xlinked osteopetrosis, lymphedema, anhidrotic ectodermal dysplasia, and immunodeficiency) has been described. (Strak and Savarirayan, 2009 ). There are nine entries for clinical types of OP in the Online Mendelian Inheritance in Man (OMIM) database (Table 1 ).
The AD variant of OP, ADO, is a milder form with an incidence of 1 : 100 000 individuals (De Vernejoul and Schulz, 2007) . It presents in late childhood or adolescence. The main presentation is confined to the skeleton with fractures, hip osteoarthritis, and osteomyelitis particularly affecting the mandible resulting in dental abscesses or caries (Benichou et al., 2000) . OMIM entries for ARO are labeled as OPT B. A number between 1 and 7 follows to differentiate subtypes with different genetic etiologies (Table 1 ). Approximately 50% of ARO is caused by mutations in TCIRG1. ARO caused by TCIRG1 mutations is difficult to distinguish from CLCN7-related disease (Frattini et al., 2000; Kornak et al., 2000) . OSTM1 mutations account for 2% of ARO and seem to cause an extremely severe form with frequent central nervous system involvement (Pangrazio et al., 2006) . Approximately 15% of all ARO is secondary to CLCN7 mutations. Global developmental delay and seizures are frequent in the autosomal recessive osteopetrosis type (De Vernejoul and Schulz, 2007) . Fifteen percent of the mutations found in ARO are nonsense mutations and 85% are missense mutations. Approximately 25% of these mutations reside in the c-terminal CBS domains of the protein. Nonsense mutations in CLCN7 are more likely to cause ARO (De Vernejoul and Schulz, 2007) . A rare form includes ARO with renal tubular acidosis. (Driessen et al., 2003) . OPT B2 and OPT B7 are rare osteoclast-poor forms that differ in their response to HSCT.
Neuropathic osteopetrosis
A rare subset of ARO is the so-called neuropathic form. In this case, primary neurological and retinal degeneration occurs. This contrasts with the other types in which the neurological manifestations are secondary to the skull hyperostosis. The neuropathic form more closely resembles a neurodegenerative disorder. It is characterized by developmental delay, hypotonia, cerebral atrophy, retinal dystrophy, and sensorineural deafness and seizures in the absence of hypocalcaemia (Maranda et al., 2008) . CLCN7 knockout mice have also shown neurodegeneration (Kasper et al., 2005) . The basis of this form of OP is still incompletely understood. Preliminary studies suggest that the neuropathic form may be more likely linked to mutations in the CLCN7 gene (De Vernejoul and Schulz, 2007) . This study with a CLCN7 mutation and early onset of neurologic manifestations supports this view.
Onset of intermediate autosomal OP (IAO) occurs in childhood; findings may include fractures after minor trauma, characteristic skeletal radiographic changes found incidentally, mild anemia, and occasional visual impairment secondary to optic nerve compression. Life expectancy in IAO is usually normal (Strak and Savarirayan, 2009) . Most cases are due to mutations in the CLCN7 gene (Table 1) . OPT B6 is a less common intermediate form of OP and results from mutations in PLEKHM 1.
From the above clinical classification, it is interesting to note that CLCN7-related OP can be classified into three forms: AD, AR, and IAO. (Besbas et al., 2009 ) Nonsense mutations in CLCN7 gene are more likely to cause ARO. The proportion of mutations in the C-terminal CBSdomains of the chloride channel type 7 is higher in ADO II than in ARO (De Vernejoul and Schulz, 2007) .
The differential diagnosis of OP includes some rare bone disorders such as pycnodysostosis (Baker et al., 1973) , dysosteosclerosis (Elcioglu et al., 2002) , and osteopoikilosis (Ghai et al., 2003) .
Molecular genetics
DNA analysis in our patient revealed a homozygous c.688A > G transition in exon 8 of the CLCN7 gene. This change converts a codon for lysine (AAA) to a codon for glutamic acid (GAA). The significance of the variations was determined by comparison with wild-type sequences, previously reported mutations, and correlations with chloride channel 7 protein structure. To the best of our knowledge, this change has not been reported as either a mutation or a polymorphism. However, comparison of chloride channel 7 amino acid sequences derived from numerous species indicates that lys230 is highly conserved, in 15 of the 16 species excluding Drosophila melanogaster. Disturbance of osteoclast function due to mutation in a gene encoding an osteoclast-specific subunit of the vacuolar proton pump (TCIRG1) are found in most patients with the recessive form. Mutations of the chloride channel protein, CLCN7, are found in the dominant form. Both types lead to disturbance of acidification needed for normal osteoclast function.
Lysine in the 231th position of the human CLCN-1 was shown to be critical for ion selectivity in CLCN-1 (Fahlke , 1997) . Charge inversion at position 231 (p.Lys231Glu) in CLCN-1 caused an increased ion permeability. In our patient, lysine at position 230 also changed to glutamic acid. With regard to the neurological features in our patient, a logical explanation could be that amino acid substitution in this conserved position perturbs the ion conductivity of the channel, which leads to the neurological features.
Osteopetrosis among arabs
A review of reported cases of OP suggests that it is relatively common in the Arab world (Zlotogora, 1997; Shalev et al., 2001 ; OP, AR 1; Center for Arab Genomic Studies), and that the most commonly reported variety is the severe AR type with onset in infancy and with severe neurological involvement (Table 2) . This contrasts with studies from other parts of the world where CLCN7-related ARO accounts for 15% of all cases. The bias toward reporting the more severe phenotype remains a possibility. We did not find any information with regard to the genotype in any of the Arab reported patients, but we suspect that these cases most closely resemble the neuropathic form phenotypically.
Molecular testing of further Arab patients may prove that this type of mutation is recurrent or that the range of mutations causing ARO is different from that reported from the western world and has a unique pattern. It may also provide evidence for founder effects, and important phenotype-genotype correlation data. To our knowledge, this is the first study of OP in a Yemeni family and the first study of a genetic mutation in an Arabic patient. It is also the first study of this specific mutation in the literature.
In addition, the result of our study suggests that the neuropathic form may be more common in the Arabs (Zlotogora, 1997; Shalev et al., 2001 ). This has considerable clinical implications. First, it provides further evidence that CLCN7 mutations may be more closely linked with the neuropathic form than other genes, an important phenotypic-genotypic correlation. This is very important, not just from a counseling point of view, but if further evidence accumulates; finding a CLCN7 mutation in such patients can guide management decisions as the neurogenerative form does not respond to HSCT. Second, it suggests that in Arab patients with ARO (especially with early onset and neurologic manifestations), it may be more feasible to start molecular genetic testing by searching for mutations in the CLCN7 gene rather than the TCIGRI gene as is a common practice in 'Western' laboratories where ARO is more commonly associated with mutations in this latter gene. 
